Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Chun Chieh Lin, PhD, MBA, Matthew P

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience Debra P. Ritzwoller, PhD, Nikki.

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer? Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Long-Term Results of Radiofrequency Ablation Treatment of Stage I Non-small Cell Lung Cancer: A Prospective Intention-to-Treat Study Marcello Carlo Ambrogi,

Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.

It’s All in the “Swerve of the Curve”

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed Steven Chuan-Hao Kao,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Mott Frank E. , MD, Sharma Neeraj , MD, Ashley Pandora CHEST

Presentation transcript:

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, Brian C. McCaughan, MBBS, FRACS Journal of Thoracic Oncology Volume 6, Issue 10, Pages 1691-1696 (October 2011) DOI: 10.1097/JTO.0b013e31822647fd Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier survival curves for node-negative non-small cell lung cancer (NSCLC) by cell type (log rank p = 0.001). Journal of Thoracic Oncology 2011 6, 1691-1696DOI: (10.1097/JTO.0b013e31822647fd) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier survival curves for node-negative non-small cell lung cancer (NSCLC) by American Joint Committee on Cancer (AJCC)-7 T stage (log rank p < 0.0001). Journal of Thoracic Oncology 2011 6, 1691-1696DOI: (10.1097/JTO.0b013e31822647fd) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier survival curves for node-negative subjects within T stage, by T-stage descriptors. A, T2 (log rank p = 0.19). B, T3 (log rank p = 0.75). Journal of Thoracic Oncology 2011 6, 1691-1696DOI: (10.1097/JTO.0b013e31822647fd) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions